Peptides are an important class of drugs, but their potential for treating
chronic diseases will be fully realized only if more acceptable delivery
methods than daily injections can be developed. Recognition of this has led to
advances in oral, intranasal, inhaled, transdermal, and buccal formulations.
This report analyses the products and companies at the forefront of such
research.
FEATURES AND BENEFITS
Assess the breadth of innovations that have been applied to the delivery
of peptide drugs.
Compare the various technologies developed for use within particular
indications.
Evaluate the merits and limitations of each company's peptide delivery
solutions.
Gain insight from analysis of the patents filed to protect specific
delivery technologies.
Understand the technical principles on which the delivery technologies are
based.
HIGHLIGHTS
The demise of Exubera, an inhaled insulin product, has had a knock-on effect
on the inhaled insulin technologies and there are now few still in
development, despite products offering strong advantages such as fast
absorption, fast onset of action, and a non-invasive mode of administration.
New oral nanotechnology peptide formulations are showing promise, particularly
in the area of insulin and GLP-1 analog delivery. New long-acting peptides and
controlled release injectable formulations are extending peptide half-lives
significantly, leading to weekly and even monthly subcutaneous injectable
formulations.
First- and second-generation transdermal patch technologies were not suitable
for peptide drug delivery due to the need for low molecular weight and low
dose loading, but third-generation patch technologies (such as thermal
ablation, microneedles, vesicular carriers, and iontophoresis) are offering
promise in the delivery of several peptides.
YOUR KEY QUESTIONS ANSWERED
What type of delivery technologies are available to those developing
peptide therapeutics?
What peptide delivery challenges are the innovations intended to overcome?
Which indications offer the greatest advances by investment in delivery
technologies?
Which companies have already formed partnerships with the inventors of
cutting-edge delivery techniques?
What hurdles remain for specific technologies and how far are they from
being employed in a commercialized drug?
Table of Contents
Table of Contents
About the author
Disclaimer
EXECUTIVE SUMMARY
Peptide delivery technologies overview
Innovations in peptide delivery for diabetes and obesity
Innovations in peptide delivery for osteoporosis and other bone diseases
Innovations in peptide delivery for cardiovascular diseases
Innovations in peptide delivery for CNS and inflammatory diseases
Innovations in peptide delivery for GI diseases, cancer, and hormonal
conditions
Peptide delivery technology overview
Summary
Introduction
Issues in the development of therapeutic peptides
Benefits of less-invasive modes of administration
Key parameters
Developments in injectable peptide delivery
Challenges of oral peptide delivery
Degradation of peptides in the digestive tract
Peptides may have a narrow window of absorption from the GI tract
Mechanisms of transport across the gastrointestinal mucosa
Technologies used in oral delivery of therapeutic peptides
Enzyme inhibitors
Permeation enhancers
Mucoadhesives
Encapsulation technologies
M-cell targeting
Companies involved in oral delivery of peptides
Unigene's Enteripep technology
Aegis Therapeutics' Intravail technology
Oramed's oral peptide delivery technology
Merrion's GIPET technology
Biodel's VIAtab technology
Emisphere's Eligen technology
Bone Medical and Diabetology's Axcess technology
Nanotechnology used in the oral delivery of peptides
Figure: Long-acting GLP-1 receptor agonists for subcutaneous injection
Innovations in the Delivery of Peptides published by Business Insights in May 31, 2012. This report consists of Pages: 241 and the price starts from US $ 3835.
